Inflammatory Gene Expression, Insulin Resistance, and Circulating Markers Vary by Visceral Adiposity in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease

These findings highlight differential immune changes across visceral adiposity levels in MASLD, supporting the need for tailored interventions based on adiposity profiles.